-
公开(公告)号：US20200024311A1
公开(公告)日：2020-01-23
申请号：US16574500
申请日：2019-09-18
Applicant: NOVARTIS AG
Inventor： Matthew T. Burger , Yunho Jin , Tetsuo Uno
Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e. Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:
-
公开(公告)号：US20230081720A1
公开(公告)日：2023-03-16
申请号：US17613020
申请日：2020-05-19
Applicant: NOVARTIS AG , LES LABORATOIRES SERVIER
Inventor： Matthew T. Burger , Maia Chanrion , Frédéric Colland , Marton Csekei , Lea Delacour , Patrice Desos , Olivier Geneste , Jean-Michel Henlin , Vesela Kostova , Andras Kotschy , Ana Leticia Maragno , Eric McNeill , Mark G. Palermo , Francesca Rocchetti , Jérôme Starck , Bing Yu , Qiang Zhang , Ágnes Proszenyák , Szabolcs Sipos , Zhuoliang Chen , Katsumasa Nakajima , Joseph Anthony D'Alessio , John William Blankenship
IPC: A61K47/68
Abstract: Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
-
公开(公告)号：US10464969B2
公开(公告)日：2019-11-05
申请号：US16098289
申请日：2017-05-03
Applicant: NOVARTIS AG
Inventor： Matthew T. Burger , Yunho Jin , Tetsuo Uno
Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:
-
公开(公告)号：US20190144504A1
公开(公告)日：2019-05-16
申请号：US16098289
申请日：2017-05-03
Applicant: NOVARTIS AG
Inventor： Matthew T. Burger , Yunho Jin , Tetsuo Uno
CPC classification number: C07K7/64 , A61K47/6831 , A61K47/6849 , A61K47/6851 , A61K47/6863 , A61P35/00 , C07K16/32 , C07K2318/10
Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:
-
-
-
Search Results
14
records
(took 0.023 seconds)
